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Abstract 
 
Background and purpose: Butyrate has shown benefits in inflammatory bowel diseases 
(IBD). However, its oral administration is infrequent due to rancid smell and unpleasant taste. 
The efficacy of a more palatable butyrate-releasing derivative, N-(1-carbamoyl-2-
phenylethyl) butyramide (FBA), was evaluated in a mouse model of colitis induced by 
dextran sodium sulphate (DSS).  
 
Experimental approach: Male 10-week-old BALB/c mice received DSS (2.5%) in drinking 
water (for 5d) followed by DSS-free water for 7d (DSS group). Oral FBA administration 
(42.5 mg∙kg-1) started 7d before DSS as preventive (P-FBA), or 2d after DSS as therapeutic 
(T-FBA), and both treatments lasted at 19d. One DSS-untreated group received only tap 
water (CON) for totally 4 groups. 
 
Key results: FBA treatments reduced colitis symptoms and colon damage. P-FBA and T-
FBA significantly decreased polymorphonuclear cell infiltration score compared to the DSS 
group. FBA revert the imbalance between pro- and anti-inflammatory cytokines (reducing 
inducible NOS protein expression, chemokine (C-C motif) ligand 2 and IL-6 transcripts in 
colon and increasing TGF-β and IL-10). Morever, P-FBA and T-FBA limit neutrophil 
recruitment (by expression and localization of the neutrophil granule protease Ly-6G), restore 
deficiency of butyrate transporter and improve intestinal epithelial integrity, preventing tight-
junction impairment (zonulin-1 and occludin). FBA, such as its parental compound sodium 
butyrate, inhibits histone deacetylase-9 and restores H3 histone acetylation, exerting an anti-
inflammatory activity through NF-B inhibition and PPAR-γ up-regulation. 
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Conclusions and implications: FBA reduces inflammatory intestinal damage in mice 
indicating its potential as post-biotic derivative, to overcome the limits of sodium butyrate’s 
oral administration. 
 
Key words: DSS colitis, short chain fatty acids, postbiotic, Annexin A1, HDAC-inhibitor, 
NF-κB, PPAR-γ, tight-junctions. 
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LIGANDS 
Annexin I 
Butyrate 
CCL2 
IL-6 
IL-10 
TGF-b 
 
TARGETS  
Other protein 
targets
a 
Enzymes
d 
TNF-α HDAC9 
GPCRs
b iNOS 
FFA2 receptor MPO 
FPR1 Nuclear hormone 
receptors
e 
FPR2 PPAR-γ 
Transporters
c  
MCT-1  
 
These Tables of Links list key protein targets and ligands in this article that are hyperlinked 
to corresponding entries in http://www.guidetopharmacology.org, the common portal for data 
from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are 
permanently archived in The Concise Guide to PHARMACOLOGY 2015/16 (
a,b,c,d,e
 
Alexander et al., 2015a,b,c,d,e). 
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Abbreviations used: Anx-A1 and Anxa1, Annexin A1; Ccl2, chemokine (C-C motif) ligand 
2; CON, control; DSS, dextran sodium sulphate; Ffar2, free fatty acid receptor 2; Fpr1/2, 
formyl peptide receptor 1 and 2; GPR43, G-protein coupled receptor 43; HDAC9, histone 
deacetylase 9; IBD, inflammatory bowel disease; Il6 and Il10, interleukin 6 and 10; Ly-6G 
and Ly6g, lymphocyte antigen 6; MCT-1, monocarboxylate transporter; MPO, 
myeloperoxidase; NF-κB, nuclear factor-κB; iNOS, inducible nitric oxide synthase; Ocln, 
occludin; P-B, sodium butyrate as preventive treatment; P-FBA, N-(1-carbamoyl-2-
phenylethyl) butyramide as preventive treatment; PMNs, polymorphonuclear cells; PPAR-γ, 
peroxisome proliferator-activated receptor gamma; SCFAs, short-chain fatty acids; Slc16a1, 
solute carrier family 16 (monocarboxylic acid transporters), member 1; Tgfb, transforming 
growth factor-β; T-B, sodium butyrate as therapeutic treatment; T-FBA, N-(1-carbamoyl-2-
phenylethyl) butyramide as therapeutic treatment; Tnf, tumour necrosis factor-α; Tregs, 
regulatory T cells; TJ, tight junction; Tjp1, tight junction protein 1; UC, ulcerative colitis; 
ZO-1, zonula occludens 1. 
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Introduction  
Host-microbial homeostasis requires appropriate immune regulation within the gut mucosa, 
preventing uncontrolled immune responses against the beneficial commensal microbiota, 
which could potentially lead to inflammatory bowel diseases (IBDs), such as ulcerative 
colitis (UC) (Geuking et al., 2014). Several studies indicate that products of bacterial 
metabolism, such as short-chain fatty acids (SCFAs), may modulate the immune response of 
the host (McDermott & Huffnagle, 2014). In particular, butyrate produced by intestinal 
microbial fermentation of undigested resistant starches and dietary fibres, is absorbed by the 
colonic cell and extensively metabolized, constituting the main source of energy. Many 
intestinal and extra-intestinal effects are ascribed to butyrate (Canani et al., 2011), showing 
its possible therapeutic indications in gastroenterology. To date, several studies have 
evaluated butyrate effectiveness in several animal model of UC (Mishiro et al., 2013; Vieira 
et al., 2012). In humans few studies have been performed probably due to low compliance 
with the oral route (for its rancid taste) or rectal enemas administration (for its cumbersome 
application to the patient and irritability due to acid property). Moreover, rectal 
administration of butyrate or mixture of SCFAs did not show beneficial effects or displayed 
only trends towards clinical amelioration (Breuer et al., 1997; Hamer et al., 2010; Scheppach 
et al., 1992; Steinhart et al., 1996; Vernia et al., 2003). The discrepancy in human studies 
using enemas may be due to differences in treatment, duration, use of butyrate alone or 
mixture of SCFAs enemas, and use of several concentrations and volumes of these mixtures. 
Conversely, other studies reported that fermentable dietary fiber supplementation, which 
resulted in increased fecal butyrate levels, was effective in maintaining remission in UC, 
revealing a significant improvement in clinical and inflammatory aspects (Fernandez-Banares 
et al., 1999; Hanai et al., 2004; Wedlake et al., 2014).The importance of butyrate 
supplementation has been demonstrated by the impaired butyrate metabolism in intestinal 
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inflamed mucosa of patients affected by IBD (De Preter et al., 2012). In fact, data show that 
butyrate deficiency results from the reduction of butyrate uptake by the inflamed mucosa due 
to down regulation of the monocarboxylate transporter (MCT)-1 expressed on the apical 
membrane of intestinal epithelium (Thibault et al., 2007). Particularly, the reduction of the 
intracellular availability of butyrate in colonic cells may decrease its protective effects toward 
cancer in IBD patients (Thibault et al., 2010). 
GPR43 is a G-protein-coupled receptor expressed in colonic epithelium, adipose tissue and 
immune cells (Bindels et al., 2013) and together with GPR109A are considered the main 
butyrate targets involved in suppression of colonic inflammation and carcinogenesis (Singh et 
al., 2014). Moreover, butyrate modulates histone acetylation, as histone deacetylase (HDAC) 
inhibitor, and alters host epigenome, leading to its epigenetic mechanism (Canani et al., 2011; 
Hamer et al., 2008).  
On the basis of all its characteristics, butyrate can be considered a postbiotic being a non-
viable bacterial metabolic product obtained from probiotic microorganisms that have biologic 
activity in the host. The purpose of this study was to investigate the efficacy of more 
palatable butyrate-releasing compound, the N- (1-carbamoyl-2-phenyl-ethyl) butyramide 
(FBA), in dextran sodium sulphate (DSS)-induced colitis model as innovative post-biotic 
derivative. Our hypothesis is that FBA similarly or better than its parental compound (sodium 
butyrate) is able to reduce colon imflammation and colitis symptoms by decreasing 
neutrophils recruitment and the production/release of pro-inflammatory mediators in the 
colonic mucosa following DSS exposure. The mechanisms behind these effects could be 
related to the restoration of butyrate transporter, PPAR-γ and tight junctions in colon tissue 
together with the HDAC9/NF-B axis inhibition. 
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Methods 
Reagents and diet. Prof. Antonio Calignano provided FBA (International application patent 
with publication number WO2009130735), whose synthesis and characterization was 
previously reported (Mattace Raso et al., 2013). FBA is stable to acids and alkalis and 
capable of releasing butyric acid at small and large bowel level in a constant manner over 
time. Interestingly, FBA does not present the unpleasant odour of butyrate and, being 
tasteless, overcomes the poor palatability of butyrate that often reduces the therapy 
compliance. All chemicals, included sodium butyrate, were purchased from Sigma-Aldrich 
(Saint Louis, MO, USA). The standard laboratory unpurified diet was purchased from Harlan 
Teklad. The 2018 Teklad Global Protein Rodent Diet contained the following: water, 120 
g∙kg-1; protein, 185 g∙kg-1; fat, 55 g∙kg-1; fiber, 45 g∙kg-1; ash, 60 g∙kg-1; minerals, 0.13 g∙kg-1 
(containing 50 mg ferrous Fe∙kg-1 and 44 mg Mn∙kg-1); and vitamin mix, 0.52 g∙kg-1 
(containing 81 mg vitamin E∙kg-1). 
 
Induction of colitis and treatments. Experimental colitis, was induced in 10-week-old 
BALB/c AnNHsd male mice (25±2 g) (Harlan-Corezzano, Italy) by 2.5% wt:vol DSS (36-50 
kDa, MP Biomedical) in drinking water ad libitum from day 7 until 12 followed by DSS-free 
water from day 13 until day 19 (end of experimental protocol). Mice were randomly divided 
into the 4 following  groups (n=10 per group): 1) control mice (CON group); 2) mice 
receiving DSS (DSS group); 3) DSS-fed mice receiving FBA as preventive therapy (P-FBA); 
4) DSS-fed mice receiving FBA therapeutically (T-FBA). Untreated CON and DSS groups 
received tap water by gavage as vehicle. 
In addition, we decided to set up two further groups of DSS-fed mice treated with its parental 
compound sodium butyrate (B): 5) DSS-fed mice receiving sodium butyrate as preventive 
therapy (P-B); 6) DSS-fed mice receiving sodium butyrate therapeutically (T-B). FBA and 
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sodium butyrate were given daily. Sodium butyrate (B, 20 mg∙kg-1) or FBA (42.5 mg∙kg-1, the 
equimolecular dose of B) was administered by gavage, and the treatment started 7 d before 
(preventive) or 2 d after (therapeutic) DSS challenge, continuing for all experimental period. 
We used the parental compound in the evaluation of body weight, disease activity index, 
colon length, histopathologic score, survival rate and mechanistic studies to confirm the 
similar profile of FBA as butyrate-releasing derivative. Mortality rate was assessed during the 
entire experimental time (from day 1 to day 19) and a Kaplan-Meier survival curve was 
calculated (Supplemental Figure 1). All procedures involving animals and their care were 
conducted in conformity with international and national law and policies (EU Directive 
2010/63/EU for animal experiments, ARRIVE guidelines and the Basel declaration including 
the 3R concept) and were approved by the Institutional Committee on the Ethics of Animal 
Experiments (CSV) of the University of Naples “Federico II” and by the Ministero della 
Salute under protocol no. 0022569-P-20/12/2010. At day 19, following an overnight fast, 
animals were killed by an intraperitoneal injection of a mixture of ketamine/xylazine 
followed by cervical dislocation. 
 
Evaluation of experimental colitis. In all mice, weight, presence of blood, and gross stool 
consistency were determined daily as previously described (Dieleman et al., 1997). Each 
score was determined as follows: 1) change in weight (0: weight loss <1% compared to the 
starting weight, 1: weight loss between 1 and 5%, 2: weight loss between 6 and 15%, 4: 
weight loss >15%); 2) stool blood (0: negative, 2: positive, 4: gross bleeding); and 3) stool 
consistency (0: normal, 2: loose stools, 4: diarrhea) as previously described (Cooper et al., 
1993). Briefly, the disease activity index was determined by combining the scores from these 
3 categories and dividing that number by 3. 
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Histological analysis and scoring of colon sections. At day 19, after mice euthanasia, tissues 
were collected and colon length was measured. Distal sections were stored in formalin 10% 
or O.C.T for histological and immunofluorescent analyses. Following H&E staining, colon 
sections were analyzed in blinded manner for the evaluation of the histopathological score as 
previously described (Chang et al., 2014). 
 
Real-time PCR. Total RNA isolated from colon was extracted using TRIzol Reagent 
(Invitrogen), according to the manufacturer’s instructions. cDNA was synthesized using a 
Maxima First Strand cDNA Synthesis Kit (Fermentas) from 2 μg total RNA. PCRs were 
performed with Bio-Rad CFX96 Connect Real-time PCR System and software (Bio-Rad 
Laboratories). The primer sequences for target genes and PCR conditions are reported in 
Supplemental Table 1.  
 
Serum TNF-α determination. At day 19, mice were euthanized and blood was collected by 
cardiac puncture. Sera were obtained by centrifugation at 1500 x g at 4°C for 15 min, and 
stored at -70°C. TNF-α levels (pg/ml) were measured by Enzyme-Linked ImmunoSorbent 
Assay (ELISA) kits for mice from BD Pharmingen, according to the manufacturer’s 
instructions. 
 
Western blotting. Colon tissue was homogenized and protein lysates were subjected to SDS-
PAGE as already described (Simeoli et al., 2015). The filters were probed with primary 
antibody overnight. To evaluate nuclear factor-κB (NF-κB) activation and histone H3 
acetylation, NF-κB p50 (Cell Signaling Technology), Acetyl-H3 and H3 (EMD Millipore) 
were measured in nuclear extracts. iNOS (Cayman Chemicals) protein expression was 
evaluated in whole colon lysates. The blot was developed using enhanced chemiluminescence 
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detection reagents (Amersham Pharmacia Biotech, Piscataway, NJ) and the immune complex 
visualized by Image Quant. The protein bands were scanned and densitometrically analyzed 
with a model GS-700 imaging densitometer (Bio-Rad Laboratories). Western blots for Lamin 
A and GAPDH (Sigma-Aldrich) were performed to ensure equal sample loading in nuclear 
and whole lysates, respectively. 
 
Measurement of myeloperoxidase (MPO) activity. Proximal colonic tissues were 
homogenized according to (Bradley et al., 1982). The homogenates were assessed for 
myeloperoxidase (MPO) activity as previously described (Smith & Castro, 1978). MPO was 
expressed as units/mg protein with 1unit hydrolyzing 1 μmol H2O2/min. 
 
Immunofluorescence analysis of Ly-6G and Annexin A1. Colon samples for 
immunofluorescence were embedded in O.C.T. (PelcoCryo-Z-T, Ted Pella Inc), and 
cryosectioned (10 µm thick). Tissue sections were then fixed in 4% paraformaldehyde for 10 
min at room temperature (RT). To examine co-localization of Anx-A1(Annexin A1) with Ly-
6G (lymphocyte antigen 6), sections were blocked and then incubated with a monoclonal 
antibody anti Ly-6G FITC (BD Biosciences) and a rabbit anti-AnxA1 antibody overnight at 
4°C. Sections were then incubated with Alexa-Fluor
®
 546 goat anti-rabbit IgG (Invitrogen) 
for AnxA1 1h at RT. After incubation with secondary antibody, sections were incubated with 
DAPI to visualize nuclei. Fluorescence was visualized with Olympus BX51 fluorescence 
microscope (Olympus) equipped with a DS-QiMc monochromatic camera (Nikon) and X-
Cite® Series 120Q Xenon lamp. NIS-Elements BR3.1 software (Nikon) was used for all 
analyses. Merge images were performed with ImageJ
®
 software. Two negative controls were 
used: slides incubated with or without primary antibody. Images were recorded at identical 
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gain settings, and performed in duplicate in non-serial distant sections. Four image fields 
were taken of each section. 
 
Immunofluorescence analysis of Occludin and Zonula occludens (ZO)-1. Colon segments 
were fixed in 10% formalin and embedded in paraffin. 7 µm sections were deparaffinised in 
decreasing ethanol percentage and antigens were unmasked. After antigens retrieval, sections 
were permeabilized in Tris-buffered saline (TBS) plus 0.1% Triton X-100. After non specific 
background blocking sections were incubated with anti-occludin or anti-ZO-1 (1:50 for 
occludin Santa Cruz Biotechnology and 1:100 for ZO-1 Invitrogen). Sections were probed 
with secondary Alexa Fluor
®
 488 antibody (1:200, Invitrogen Corporation). Slides were  
visualized on a fluorescence microscope and images were stored digitally with Leica 
software. Two negative controls were used: slides incubated with or without primary 
antibody. The quantitative measurements of immunofluorescence analysis for Occludin and 
ZO-1 was performed and revealed by Integrated Pixel Intensity using an ImageJ
®
 software. 
 
Statistical analysis. All data are presented as means ± SEMs. The statistical analyses were 
performed with the use of Graph-Pad Prism (Graph-Pad Software). For all the experimental 
data, we evaluated group differences with one-way analysis of variance (ANOVA) followed 
by Bonferroni multiple comparison test. For the analysis of the body weight changes during 
the entire experimental period, we used two-way ANOVA followed by Tukey multiple 
comparison test, setting as variables the treatment and the time. Survival study was analyzed 
using the Kaplan-Meier log-rank test.  Statistical significance was set at P<0.05. 
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Results 
 
FBA similarly to butyrate reduces disease activity index and colon tissue damage. The oral 
treatment with P-FBA and T-FBA  significantly reduced the development of colitis evaluated 
by disease activity index (DAI) at day 12  and 18 compared to DSS group (Figure 1A). A 
similar effect was observed even when DSS-mice were treated with butyrate as preventive or 
therapeutic therapy.   
Beneficial effects of FBA more then butyrate were evident also in the excised colon samples, 
revealing an improvement in the tissue shortening induced by DSS (Figure 1B). Control 
colon sections stained with H&E showed intact epithelium, well-defined crypt length, no 
edema and neutrophil infiltration in mucosa and submucosa, and no ulcers or erosions (Figure 
1C). In contrast, colon tissue from DSS group showed severe inflammatory lesions 
throughout the mucosa and loss of crypt architecture. Both FBA and butyrate were able to 
protect colonic mucosa structure, ameliorating mucosa integrity and crypt structure and 
improving epithelial surface compared to DSS group (Figure 1C). The beneficial effects 
mediated by FBA and butyrate either as preventive and therapeutic schemes, were also 
confirmed by evaluation of  histopathological score performed on distal colon sections 
stained with H&E (Figure 1D).  
The mortality rate and body weight were also monitored during all the experimental period 
(Supplemental Figure 1 and 2).  
 
Effects of FBA on neutrophil infiltration in colonic mucosa. We determined the expression 
and localization of the neutrophil granule protease Ly-6G in colon tissue by fluorescence 
microscopy (Figure 2A). To verify if protective effect of FBA was also associated with 
modulation of pro-resolving factors, such as Annexin A1, double-staining 
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immunofluorescence was performed,  revealing high Anx-A1 levels in neutrophils, confirmed 
by a marked co-localization with Ly-6G in colon of mice with active disease. Both FBA 
schemes were able to counteract neutrophil infiltration induced by DSS-challenge reducing 
the Ly-6G and Anx-A1 staining (Figure 2A). This effect was also quantitatively 
demonstrated since polymorphonuclear cells (PMNs) infiltrating score was lower in P-FBA 
and T-FBA colonic mucosa compared to DSS group (Figure 2B). Similarly, FBA, either as 
preventive or therapeutic treatment, contrasted DSS-mediated effects reducing Anxa1 mRNA 
transcripts (Figure 2C). Furthermore, in both FBA-treated groups, activity of MPO, a 
lysosomal hemoprotein found in the azurophilic granules in neutrophils (Figure 2D), and 
Ly6g mRNA levels (Figure 2E) were significantly less than in the DSS group. 
 
Effect of FBA on neutrophil markers and GPR43 expression in colonic mucosa. Butyrate can 
influence chemotaxis of immune cells through GPR43 receptor (Bindels et al., 2013). 
Therefore, we analysed mRNA levels of this receptor in colon. As depicted in figure 3A, 
FBA, especially when used as therapeutic, was able to increase significantly mRNA levels 
for Ffar2 (free fatty acids receptor-2, which encode for GPR43) compared to control and 
DSS groups. In contrast, FBA, either as preventive or therapeutic treatment, counteracted 
DSS-mediated effects reducing Fpr1 and Fpr2 mRNA levels (Figure 3B-C). These data 
highlight the involvement of GPR43 in neutrophil recruitment during colon inflammatory 
condition and confirm that FBA was able to reduce PMN infiltration compared to DSS group.  
 
FBA modulates pro-and anti-inflammatory mediators in colon and serum. Protein expression 
of inducible nitric oxide synthase (iNOS), which is responsible for NO production, and 
mRNA levels of Ccl2 gene, which encode monocyte chemoatractant protein (MCP)-1, were 
greater in the colon of DSS challenged mice rather than those of control group (Figure 4A 
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and 4B). Similarly, Tnf and Il6 mRNA levels were greater in DSS group than in CON (Figure 
4C-D). Conversely, the transcriptional levels of anti-inflammatory cytokines Il10 and Tgfb 
resulted impaired by DSS (Figure 4E-F). FBA treatments, similarly reduced proinflammatory 
iNOS and Ccl2, Tnf and Il6 and at least in part restored Il10 and Tgfb transcripts in colon 
tissue compared to DSS group. Moreover, we also analysed the TNF-α levels in serum (n=5, 
each group) to confirm the systemic anti-inflammatory properties of FBA and butyrate 
(CON=1,67±0,34 pg/ml and DSS=28,74±4,57, P<0.001; P-FBA=15,22±3,85 and T-
FBA=12,89±2,76, P<0.05 Vs DSS, respectively). 
 
FBA preserves MCT-1 transporter and epigenetically counteracts inflammation induced by 
DSS. DSS-challenged mice showed lower mRNA levels of the monocarboxylic acid carrier, 
the solute transporter family 16 Slc16a1, than the CON group (figure 5A). This reduction was 
preserved only by therapeutic treatments with FBA or butyrate. To determine the 
mechanisms involved in butyrate effect, the modulation of several transcription factors and 
histone acetylation were analyzed. DSS challenge significantly reduced the PPAR- (Pparg) 
mRNA (Figure 5B) and increased nuclear NF-κB p50 protein (Figure 5D) compared to 
control group. These effects were counteracted by preventive and therapeutic treatments with 
FBA. We also assessed the FBA capability to normalize the transcriptional levels of a 
specific member of class IIA HDAC involved in the pathogenesis of colitis in mice (de 
Zoeten et al., 2010), the HDAC9, which resulted impaired in DSS animals. As shown in 
figure 5C, FBA, such as sodium butyrate, counteracted the DSS-induced up-regulation of 
Hdac9 mRNA levels. However, FBA when used as therapeutic scheme was able to 
significantly increase histone H3 acetylation confirming HDAC inhibition (Figure 5E). 
Interestingly, FBA and butyrate did not modify histone 3 (H3) acetylation when used as 
preventive treatment.  
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Effects of FBA on intestinal barrier integrity and tight-junction expression. To evaluate 
barrier integrity, we determined the distribution of two tight junction proteins (TJs), occludin 
and ZO-1, in distal colon. Staining for occludin (Figure 6A) and ZO-1 (Figure 6C) in colonic 
mucosa of DSS-fed mice displayed less intensity than CON group, as confirmed even by the 
integrated pixel intensity analysis for occludin and ZO-1 (Figure 6B and D, respectively). 
However, compared to DSS group, P-FBA and T-FBA significantly restored the distribution 
of occludin and ZO-1, through colonic mucosa with a continuous staining pattern. These 
effects were highlighted by the evaluation of mRNA transcriptional levels for both proteins in 
colon sections (see Supplemental figure 3). Furthermore, both FBA-based treatments more 
than P-B and T-B, were able to preserve not only the TJs distribution but even the 
architecture of colons in DSS-fed mice similarly to that of control mice. 
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Discussion 
 
In this study, we demonstrated that FBA, a butyrate-releasing derivative, protects mice from 
DSS-induced colon injury, by reducing inflammation and restoring epithelial barrier integrity. 
The effects of SCFA, in particular butyrate, in intestinal diseases and their role on colonic 
functions are known (Canani et al., 2011; Hamer et al., 2008; Hamer et al., 2009). However, 
despite the wide spectrum of possible indications, the major limits of butyrate in clinical 
practice are its unpleasant taste and odour, when orally administered, or discomfort, by rectal 
preparations. Even if dietary fiber intake, leading to SCFA production, has shown benefits in 
IBD (Hanai et al., 2004; Wedlake et al., 2014), other data had demonstrated an inverse 
association between intake of fruits and vegetables and risk of IBD (Amre et al., 2007) and 
more recently dietary intake and risk of developing IBD have been reviewed 
(Ananthakrishnan et al., 2013; Hou et al., 2011). Very recently the rational identification of 
diet-derived postbiotics in restoring intestinal microbiota composition and function has been 
reviewed (Klemashevich et al., 2014). For all these reasons the use of postbiotics, such as 
butyrate, may be potential alternative to the use of live probiotic organisms or dietary fiber 
intake as prebiotics. In fact, the beneficial effects of sodium butyrate in different models of 
DSS-induced colitis in mice have been already reported after oral or topical administration 
(Mishiro et al., 2013; Vieira et al., 2012). Recently, we investigated the role of butyrate and 
FBA in pain behaviour, identifying different and converging non-genomic and genomic 
mechanisms of action, which cooperate in nociception maintenance (Russo et al., 2016). 
Notably, we found a major activity of both compounds on inflammatory visceral pain 
probably due to butyrate physiological role in gut and to the possible elevated number of its 
transporters (i.e. MCT1) involved in its absorption.  
  
This article is protected by copyright. All rights reserved. 
Here, we tested oral FBA efficacy in DSS colitis which leads to a significant loss of body 
weight, associated to diarrhea, rectal bleeding and colon shortening (Yan et al., 2009). These 
macroscopic and pathologic changes were counteracted by FBA, similarly to sodium 
butyrate, especially when used as therapeutic protocol.  
The role of immune cells infiltration in the inflammatory response during the development of 
colitis was already assessed, as well as the efficacy of butyrate supplementation in limiting 
myeloid and lymphoid cells recruitment into the colonic mucosa (Tsou et al., 2007). 
According with these findings, FBA reduced DSS-induced PMN infiltration in colonic 
mucosa, decreasing MPO activity and Ly6g mRNA levels. Ly-6G, reacting only in 
neutrophils, is a very useful marker to detect specifically cells of the neutrophil lineage (Tsou 
et al., 2007). Dense neutrophil infiltration and crypt abscess formation are pathological 
characteristics in the inflamed mucosa of UC patients (Raab et al., 1993). In fact, in Japan, 
granulocyte adsorption apheresis therapy had been reported to show a remarkable therapeutic 
effect in active UC patients (Shimoyama et al., 2001). Moreover, the faecal neutrophil-
derived biomarkers, calprotectin and lactoferrin, represent an ideal non-invasive test for 
detecting intestinal inflammation (Sipponen, 2013). These findings strengthen the pivotal role 
of neutrophils in the pathogenesis of UC. Moreover, trans-epithelial migration of PMNs from 
the microcirculation to the mucosa results in impaired barrier function and tissue destruction 
(Nusrat et al., 1997).  
Among SCFAs, butyrate can influence chemotaxis of immune cells through GPR43 receptor 
but this effect depends on the type of immune cells and butyrate concentration (Maslowski et 
al., 2009; Sina et al., 2009). Here, Ffar2 mRNA expression was increased by FBA alongside 
of the reduction of Ly6g mRNA transcripts mediated by both FBA-based treatments. These 
data confirm the involvement of GPR43 in neutrophil recruitment during inflammation and, 
at the same time, display FBA ability in reducing PMN infiltration. Therefore, we 
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hypothesize that, when neutrophil recruitment is reduced by FBA treatments, GPR43 could 
be expressed on other cell populations, e.g. intestinal enteroendocrine L and epithelial cells, 
which are involved in intestinal barrier integrity. 
We also assessed if protective effect of FBA was associated with modulation of pro-resolving 
factors, such as Annexin A1 and its receptors, Fpr1 and Fpr2. Annexin A1, a member of the 
superfamily of annexins, is a downstream mediator of glucocorticoids action (Gerke et al., 
2005). In resting conditions, neutrophils, monocytes and macrophages constitutively contain 
high levels of Annexin A1 in their cytoplasm (Mulla et al., 2005; Perretti et al., 2000), that 
are promptly secreted following cell activation (Perretti et al., 1996). Increased expression 
and secretion of Annexin A1 has been reported to occur in inflamed mucosal tissues in 
rodents and humans (Vergnolle et al., 1995; Vergnolle et al., 2004). In particular, increased 
Anx-A1 was observed in the intestinal epithelium and infiltrating leukocytes in the mucosa of 
UC patients compared with normal intestinal mucosa (Leoni et al., 2013). Anx-A1 has also 
been reported to inhibit neutrophil influx and promote neutrophil apoptosis at the site of 
resolving inflammation (Perretti et al., 1996). In our experiments, a co-localisation between 
Ly-6G and Anx-A1 positive cells was obtained: FBA reduced Anx-A1 levels as well as Ly-
6G
+
 cells. Moreover, both schemes of treatment with FBA reduced the transcriptional levels 
of Fpr1 and Fpr2. Therefore, in these settings Anx-A1 and its receptors seem to be a marker 
of neutrophil infiltration.  
Our data clearly demonstrate that the preventive and therapeutic treatments with FBA 
corrected the imbalance between pro- and anti-inflammatory mediators reducing iNOS 
protein expression and Ccl2, Tnf, and Il6 transcripts in colon tissue; at the same time both 
FBA protocols recovered, at least in part, mRNA levels of Tgfb and Il10. Consistently, 
previous data showed the reduction of several pro-inflammatory mediators in colon lamina 
propria macrophages by butyrate (Chang et al., 2014).  
  
This article is protected by copyright. All rights reserved. 
Butyrate regulates epigenetically gene expression by inhibiting HDAC, specifically class IIA 
and I (Steliou et al., 2012), and its anti-inflammatory effects are related to this mechanism in 
many cell types (Chang et al., 2014). In particular class IIA HDAC has been reported to 
suppress regulatory T cells (Tregs) expansion (Smith et al., 2013) and the inhibition of 
HDAC9 increases Treg function, reducing colitis in mice (Glauben et al., 2006). Due to 
HDAC inhibition, butyrate can avoid NF-κB activation in human colonic epithelial cells 
(CECs) (Segain et al., 2000). NF-κB regulates many cellular genes involved in early immune 
inflammatory response frequently dysregulated in IBDs (Schwab et al., 2007). Here, FBA 
reproduced the same effect of butyrate limiting the Hdac9 transcript up-regulation induced by 
DSS challenge. Accordingly, FBA, especially when used as therapeutic treatment, inhibits 
NF-κB activation and promotes histone H3 acetylation.  
Moreover, we demonstrate in vivo model that FBA restored Pparg transcription in colonic 
mucosa, confirming previous in vitro data displaying PPARγ involvement in butyrate anti-
inflammatory activity (Schwab et al., 2006). Genetic ablation of PPARγ resulted in increased 
susceptibility to experimental colitis in mice (Dubuquoy et al., 2006) and PPARγ protein 
expression is 60% lower in the inflamed colonic mucosa of UC patients than in controls 
(Dubuquoy et al., 2003). Previous data have shown that PPARγ can inhibit NF-κB activation 
and cytokine expression in monocytes and CECs (Desreumaux et al., 2001).  
Interestingly, we also observed a strong reduction of MCT1 transporter in colonic mucosa of 
DSS mice, highlighting an impairment of butyrate uptake. MCT1 plays an important role in 
the absorption of butyrate by the colonocytes (Cuff et al., 2002) and previous data report that 
butyrate stimulates MCT1 promoter activity in Caco-2, IEC-6 and in rat intestinal mucosa 
(Borthakur et al., 2012; Borthakur et al., 2008). Both therapeutic FBA and butyrate preserved 
Slc16a1 down-regulation, normalizing its transcriptional levels. These results may have 
translational potential, since down-regulation of MCT1 in IBD patients could result in 
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butyrate uptake deficiency (Thibault et al., 2010). We hypothesize that in our experimental 
conditions the stronger effect of FBA could be related not only to MCT1 induction by 
butyrate released from FBA, but also to the capability of undissociated FBA to interact and 
be carried by several members of SLCs, such as those of phenyl-alanine. 
TJ alteration in UC results in impaired barrier function, which may lead to increased uptake 
of luminal antigens and/or adjuvant that overcome the net suppressive tone of the mucosal 
immune system. SCFAs modulate key epithelial cell functions that help to maintain intestinal 
epithelial barrier integrity preventing injury (Peng et al., 2009). Analysis of the distribution 
and intensity of occludin and ZO-1 staining and mRNA confirmed the beneficial effect 
elucidated by both butyrate-based compounds. Gut permeability integrity is essential to limit 
bacterial translocation and preserves mucosal immune homeostasis. In fact, damage- and 
pathogen-associated molecular patterns penetration determines a strong recruitment of 
immune cells in impaired mucosa causing subsequent inflammation. 
In conclusions, FBA treatments confirm and improve the beneficial effect of butyrate at 
intestinal level, counteracting colon inflammation, neutrophil recruitment and alteration of 
intestinal permeability in DSS-induced colitis model. Indeed, our data indicate the potential 
clinical utility of FBA as preventive or therapeutic strategy for UC, as an optimization of a 
direct “postbiotic” approach, diversifying this treatment from prebiotic (i.e. fibers) or 
probiotic (i.e. bacteria) one. Since this synthetic derivative of butyrate does not have the 
characteristic odour of rancid cheese, it may represent a viable alternative to butyrate, 
favouring a better oral compliance and a greater effectiveness. 
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Figure 1 
Effects of FBA and butyrate on DSS-induced colitis. (A) Disease activity index (DAI) on 
day 0, 7, 12 and 18. (B) Colon length expressed in cm. (C) Distal colons were stained with 
H&E. Scale bar:100 µm. White arrows indicate areas shown in the inset squares (objective 
40X). Black arrows indicate infiltrated cells in the submucosa. (D) Histopathological scores 
were determined in a blinded fashion. Colons were excised at day 19. Data are means ± 
SEMs, n=8. ** P<0.01 and *** P<0.001 Vs CON; ## P<0.01 and ### P<0.001 Vs DSS.  
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Figure 2 
FBA reduces PMN infiltration in colonic mucosa. (A) Double-staining 
immunofluorescence detection of Anx-A1 and Ly-6G (Ly-6G+Anx-A1 yellow staining) in 
DSS compared to control and FBA groups. White arrows indicate PMN infiltrate. (B) PMN 
infiltration score was obtained by counting Ly-6G
+
 cells in four random mucosal and 
submucosal views of three different sections from the descendent colon and was expressed as 
number of cells∙mm-2. (C) Real-time PCR of Anxa1 is shown. (D) MPO activity measurement 
and Ly6g mRNA levels (E) are also reported. Real-Time data are presented as means ± 
SEMs, n=8. * P<0.05, ** P<0.01 and *** P<0.001 Vs CON; # P<0.05, ## P<0.01 and ### 
P<0.001 Vs DSS. Immunofluorescence stainings are representative of 3 slides for each 
group, magnification 200X.  
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Figure 3 
Effect of FBA on GPR43 expression and neutrophil markers in colonic mucosa. 
Transcriptional levels of Ffar2 (A), Fpr1 (B) and Fpr2 (C) were also evaluated following 
treatment with FBA (preventive and therapeutic). Real-Time PCR data are presented as 
means ± SEMs, n=8. * P<0.05 and ** P<0.01 Vs CON; # P<0.05, ## P<0.01 Vs DSS. 
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Figure 4 
FBA reduces pro-inflammatory mediators and increases anti-inflammatory markers in 
colon tissue. (A) Western blot showing iNOS protein expression. GAPDH blot was used as 
equal loading control. mRNA transcriptional levels of Ccl2 (B), Tnf (C) and Il6 (D) are also 
shown. Real-time PCR of Il10 (E) and Tgfb (F) were performed in colon from CON and DSS 
mice treated or not with FBA. Data are presented as means ± SEMs, n=8. * P<0.05, ** 
P<0.01 and *** P<0.001 Vs CON; # P<0.05 and ## P<0.01 Vs DSS.  
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Figure 5 
Mechanisms of anti-inflammatory action mediated by FBA and sodium butyrate in 
DSS-induced colon damage. (A) mRNA expression of Slc16a1, (B) Pparg and (C) Hdac9 
are shown. Real-Time PCR data are presented as means ± SEMs, n=8. (D) Western blot  
showing p50 NF-κB expression in nuclear extract is also reported. Both butyrate-based 
compounds reduced Hdac9 transcriptional levels (C) and induced histone H3 acetylation (E). 
* P<0.05, ** P<0.01 and *** P<0.001 Vs CON; # P<0.05, ## P<0.01 and ### P<0.001 Vs 
DSS.  
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Figure 6  
FBA-based compounds restore TJ-barrier function improving intestinal permeability. 
Immunofluorescence staining for occludin (A) and ZO-1 (C) in colons of DSS-fed mice 
treated or not with FBA or butyrate before or after DSS consumption is shown. Scale bar: 
100 µm. White arrows indicate areas shown in the inset squares (objective 40X). 
Quantification of occludin (B) and ZO-1 (D) expression is reported as integrated pixel 
intensity/area. Data are presented as means ± SEMs, n=4. *** P<0.001 Vs CON; ## P<0.01 
Vs DSS.  
 
